Published in Support Care Cancer on June 22, 2013
Results from the LIDO anemia survey: adherence to EORTC guidelines in cancer patients in France. Support Care Cancer (2016) 0.75
Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol (2001) 3.06
The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer (2004) 2.82
Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol (1998) 2.74
Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res (2006) 2.69
Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression. J Clin Oncol (2007) 2.10
Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. J Pain Symptom Manage (1999) 1.89
NCCN Practice Guidelines for Cancer-Related Fatigue. Oncology (Williston Park) (2000) 1.88
The relationship between fatigue and sleep in cancer patients: a review. Eur J Cancer Care (Engl) (2001) 1.52
Systematic review and meta-analysis of psychological and activity-based interventions for cancer-related fatigue. Health Psychol (2007) 1.51
Values of sleep/wake, activity/rest, circadian rhythms, and fatigue prior to adjuvant breast cancer chemotherapy. J Pain Symptom Manage (2007) 1.51
Revealing response shift in longitudinal research on fatigue--the use of the thentest approach. Acta Oncol (1999) 1.48
Altered cortisol response to psychologic stress in breast cancer survivors with persistent fatigue. Psychosom Med (2005) 1.48
Cancer-related fatigue and sleep disorders. Oncologist (2007) 1.47
Inflammatory responses to psychological stress in fatigued breast cancer survivors: relationship to glucocorticoids. Brain Behav Immun (2006) 1.47
Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer (2003) 1.37
T-cell homeostasis in breast cancer survivors with persistent fatigue. J Natl Cancer Inst (2003) 1.33
The influence of daytime inactivity and nighttime restlessness on cancer-related fatigue. Oncol Nurs Forum (1999) 1.31
Cancer-related fatigue: state of the science. PM R (2010) 1.21
I'm so tired: biological and genetic mechanisms of cancer-related fatigue. Qual Life Res (2010) 1.16
Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. Br J Cancer (2001) 1.10
Fatigue and physical activity in older adults with cancer: a systematic review of the literature. Cancer Nurs (2007) 1.00
Association between fatigue and other cancer-related symptoms in patients with advanced cancer. Support Care Cancer (2008) 0.97
Management of anemia in cancer patients. Future Oncol (2011) 0.94
Age, anemia, and fatigue. Semin Oncol (2002) 0.93
Factors predicting fatigue in breast cancer patients. Support Care Cancer (2003) 0.93
Factors predicting clinically significant fatigue in women following treatment for primary breast cancer. Support Care Cancer (2010) 0.92
Is cancer-related fatigue more strongly correlated to haematological or to psychological factors in cancer patients? Support Care Cancer (2007) 0.92
Review article: a systematic review of cancer-related fatigue measurement questionnaires. Am J Hosp Palliat Care (2010) 0.90
Quality criteria and user-friendliness in self-reported questionnaires on cancer-related fatigue: a review. J Clin Epidemiol (2010) 0.87
Fatigue patterns and correlates in male liver cancer patients receiving transcatheter hepatic arterial chemoembolization. Support Care Cancer (2004) 0.84
Epoetin in cancer-related anaemia. Nephrol Dial Transplant (1999) 0.83
Anemia in oncology practice: relation to diseases and their therapies. Am J Clin Oncol (2002) 0.83
Anemia of hematologic malignancies: what are the treatment options? Semin Oncol (2002) 0.83
Anemia and fatigue in cancer patients. Cancer (2001) 0.83
The association between anemia and fatigue in patients with advanced cancer receiving palliative care. J Palliat Med (2005) 0.81
Development of a new questionnaire to assess patient perceptions of cancer-related fatigue: item generation and item reduction. Value Health (2008) 0.81
Recombinant human erythropoietin (rHuEPO) therapy in patients with cancer-related anaemia: what have we learned? Med Oncol (1998) 0.79
Patients' perception of cancer-related fatigue: results of a survey to assess the impact on their everyday life. Clin Transl Oncol (2008) 0.79
Cancer-related fatigue. Acta Clin Belg (2011) 0.79
Assessing the effect of darbepoetin alfa on patient-reported fatigue in chemotherapy-induced anemia in four randomized, placebo-controlled clinical trials. Qual Life Res (2011) 0.79
Quality of life in patients with chronic myeloid leukemia after unrelated donor bone marrow transplantation. Cancer Nurs (1999) 0.78
Psychometric properties of the Perform Questionnaire: a brief scale for assessing patient perceptions of fatigue in cancer. Support Care Cancer (2010) 0.77
Effectiveness of darbepoetin alfa in a cohort of oncology patients with chemotherapy-induced anaemia. Relationship between variation in three fatigue-specific quality of life questionnaire scores and change in haemoglobin level. Clin Transl Oncol (2011) 0.77
Plasma erythropoietin concentrations in patients receiving intensive platinum or nonplatinum chemotherapy. Br J Clin Pharmacol (2000) 0.77
Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly. Support Care Cancer (2007) 0.76
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst (2008) 3.60
Interstitial pneumonitis after oxaliplatin treatment in colorectal cancer. Clin Transl Oncol (2005) 1.72
[Validation of the Spanish version of the Brief Pain Inventory in patients with oncological pain]. Med Clin (Barc) (2003) 1.26
CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. J Exp Med (2003) 1.25
Clinical patterns over time in irritable bowel syndrome: symptom instability and severity variability. Am J Gastroenterol (2004) 1.23
Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Res Treat (2010) 1.22
Irritable bowel syndrome subtypes according to bowel habit: revisiting the alternating subtype. Eur J Gastroenterol Hepatol (2003) 1.20
Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer. J Clin Oncol (2007) 1.16
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. Breast Cancer Res Treat (2013) 1.10
Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study. J Clin Oncol (2013) 1.05
[Validation of the Spanish versions of the Montgomery-Asberg depression and Hamilton anxiety rating scales]. Med Clin (Barc) (2002) 1.04
An epidemiological evaluation of the prevalence of malnutrition in Spanish patients with locally advanced or metastatic cancer. Clin Nutr (2005) 0.96
Differences between physician and patient in the perception of symptoms and their severity in COPD. Respir Med (2013) 0.96
Splitting irritable bowel syndrome: from original Rome to Rome II criteria. Am J Gastroenterol (2004) 0.95
COPD severity score as a predictor of failure in exacerbations of COPD. The ESFERA study. Respir Med (2011) 0.95
Initially metastatic breast carcinoma has a distinct disease pattern but an equivalent outcome compared with recurrent metastatic breast carcinoma. Cancer (2004) 0.94
New synthetic inhibitors of fatty acid synthase with anticancer activity. J Med Chem (2012) 0.93
Burden of illness in irritable bowel syndrome comparing Rome I and Rome II criteria. Pharmacoeconomics (2002) 0.92
HER2 (erbB-2)-targeted effects of the omega-3 polyunsaturated fatty acid, alpha-linolenic acid (ALA; 18:3n-3), in breast cancer cells: the "fat features" of the "Mediterranean diet" as an "anti-HER2 cocktail". Clin Transl Oncol (2006) 0.91
Primary aortic sarcoma with widespread vascular embolic metastases. Eur J Intern Med (2003) 0.89
Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study. Clin Cancer Res (2009) 0.89
International development of the Parents' Index of Quality of Life in Atopic Dermatitis (PIQoL-AD). Qual Life Res (2005) 0.87
Trastuzumab in small tumours and in elderly women. Cancer Treat Rev (2013) 0.87
An unusual metastatic renal cell carcinoma with maintained complete response to sunitinib treatment. Case Rep Oncol (2011) 0.87
Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma. Cancer (2002) 0.86
Adjuvant chemotherapy for stages II, III and IV of colon cancer. Clin Transl Oncol (2009) 0.86
Integration of panitumumab into the treatment of colorectal cancer. Crit Rev Oncol Hematol (2009) 0.85
A new criterion by which to discriminate between patients with moderate allergic rhinitis and patients with severe allergic rhinitis based on the Allergic Rhinitis and its Impact on Asthma severity items. J Allergy Clin Immunol (2007) 0.85
Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells. Int J Cancer (2014) 0.84
EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt. Neoplasia (2007) 0.84
Treatment of cancer pain: Spanish Society of Medical Oncology (SEOM) recommendations for clinical practice. Clin Transl Oncol (2012) 0.82
Development of a new questionnaire to assess patient perceptions of cancer-related fatigue: item generation and item reduction. Value Health (2008) 0.81
Long-term follow-up of an anthracycline-containing metronomic chemotherapy schedule in advanced breast cancer. Breast J (2009) 0.81
Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). Clin Transl Oncol (2009) 0.80
Validation of the first treatment-specific questionnaire for the assessment of patient satisfaction with allergen-specific immunotherapy in allergic patients: the ESPIA questionnaire. J Allergy Clin Immunol (2013) 0.80
Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors. J Clin Oncol (2005) 0.79
Role of tyrosine kinase inhibitors in the treatment of advanced colorectal cancer. Clin Colorectal Cancer (2007) 0.79
Patients' perception of cancer-related fatigue: results of a survey to assess the impact on their everyday life. Clin Transl Oncol (2008) 0.79
Validation of the Spanish version of the Liverpool Adverse Events Profile in patients with epilepsy. Epilepsy Behav (2009) 0.79
SEOM clinical guidelines: a consolidated project. Clin Transl Oncol (2012) 0.79
Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients. Expert Opin Pharmacother (2011) 0.78
Participation and detection rates by age and sex for colonoscopy versus fecal immunochemical testing in colorectal cancer screening. Cancer Causes Control (2014) 0.78
Development and validation of a new Spanish instrument to measure health-related quality of life in patients with allergic rhinitis: the ESPRINT questionnaire. Value Health (2007) 0.78
Advanced breast cancer: chemotherapy phase III trials that change a standard. Anticancer Drugs (2007) 0.78
Development of a questionnaire to assess patient satisfaction with allergen-specific immunotherapy in adults: item generation, item reduction, and preliminary validation. Patient Prefer Adherence (2011) 0.77
Psychometric properties of the Perform Questionnaire: a brief scale for assessing patient perceptions of fatigue in cancer. Support Care Cancer (2010) 0.77
Serum endostatin and bFGF as predictive factors in advanced breast cancer patients treated with letrozole. Clin Transl Oncol (2006) 0.76
New primary ipsilateral metachronous breast tumor: a case report. Case Rep Oncol (2012) 0.75
Integrating trastuzumab in the treatment of breast cancer. Current status and future trends. Clin Transl Oncol (2005) 0.75
[Complications of intramuscular metastasis in a patient with lung cancer]. Med Clin (Barc) (2010) 0.75
Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer. Crit Rev Oncol Hematol (2012) 0.75
An easy, rapid and objective mathematical method to identify fatty acid synthase (oncogenic antigen-519) modulators with potential anticancer value. Clin Transl Oncol (2008) 0.75
Darbepoetin alfa administered once every three weeks for the treatment of anemia in elderly patients with non-myeloid tumors receiving chemotherapy. Tumori (2014) 0.75